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# Data availability
The datasets produced in this study are available in the following databases:
-RNA-Seq data: Gene Expression Omnibus GSE46843 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46843) -[data type]: [name of the resource] [accession number/identifier/doi] ([URL or identifiers.org/DATABASE:ACCESSION]) *** Note -All links should resolve to a page where the data can be accessed. *** Moreover, I have these editorial requests: 6) We strongly encourage the publication of original source data with the aim of making primary data more accessible and transparent to the reader. The source data will be published in a separate source data file online along with the accepted manuscript and will be linked to the relevant figure. If you would like to use this opportunity, please submit the source data (for example scans of entire gels or blots, data points of graphs in an excel sheet, additional images, etc.) of your key experiments together with the revised manuscript. If you want to provide source data, please include size markers for scans of entire gels, label the scans with figure and panel number, and send one PDF file per figure.
7) Our journal also encourages inclusion of *data citations in the reference list* to directly cite datasets that were re-used and obtained from public databases. Data citations in the article text are distinct from normal bibliographical citations and should directly link to the database records from which the data can be accessed. In the main text, data citations are formatted as follows: "Data ref:
Smith et al, 2001" or "Data ref: NCBI Sequence Read Archive PRJNA342805, 2017". In the Reference list, data citations must be labeled with "[DATASET]". A data reference must provide the database name, accession number/identifiers and a resolvable link to the landing page from which the data can be accessed at the end of the reference. Further instructions are available at: http://www.embopress.org/page/journal/14693178/authorguide#referencesformat 8) Regarding data quantification and statistics, can you please specify, where applicable, the number "n" for how many independent experiments (biological replicates) were performed, the bars and error bars (e.g. SEM, SD) and the test used to calculate p-values in the respective figure legends. Please provide statistical testing where applicable, and also add a paragraph detailing this to the methods section. See: http://www.embopress.org/page/journal/14693178/authorguide#statisticalanalysis 9) Please format the references according to our journal style. See: http://www.embopress.org/page/journal/14693178/authorguide#referencesformat I look forward to seeing a revised version of your manuscript when it is ready. Please let me know if you have questions or comments regarding the revision.
---------------
REFEREE REPORTS

Referee #1:
The authors of this interesting manuscript report a negative impact on Lgr5+ ISCs after constitutive Mex3a knockout. This study builds on a previous study by Barriga et al. 2017 by characterizing Mex3a expression in intestinal crypts and showing a role for Mex3a in intestinal epithelium maturation. In addition, they demonstrate that Mex3a null mice exhibit PPARγ activation in intestinal crypts in vivo, and that overactivation of the pathway in vitro results in impaired organoid formation. The authors provide suggestive results linking MEX3A and PPAR signaling to ISCs postnatal maintenance. However, in order to support their conclusions and definitively show that there is a requirement for Mex3a for ISC development or maintenance, the authors should address the following comments.
Major comments: 1. Figure 1 should be moved to supplementary material or added as a panel to Figure 2 . The expression pattern of Mex3a has already been characterized by Barriga et al. Further, the colon panels do not add to the story, since the entire manuscript focuses on the small intestine. Finally, the authors should clarify the difference between Mex3a expression seen in the Barriga et al. paper, i.e. in +3-4 ISCs, and the expression they report here at the bottom of the crypts, which as they comment later in the manuscript might be due to the early postnatal stages they are using here. 2. It will be informative to compare the villi length they measured in the already shorter ileum villi to the longer duodenum villi, as the mammalian gut shows an antero-posterior development axis. The authors should also discuss the difference between the proximal and distal intestinal phenotype in Mex3a-/-mice. 3. The authors need to do a more in depth characterization of the differentiated cell types, using specific cell markers for the different cell populations, for example: MUC2, CHGA, DLCK1, sucrase-isomaltase, ALDOB. 4. Is not clear if the reduction in the number of proliferating cells reported here is due to a loss of these cells or because the crypts are smaller; it is possible that the proportion of proliferating cells are maintained. Proliferating cells should be quantify and corrected by crypt size or quantified using FACS. 5. The authors state that there is a reduction in the amount of Olfm4 transcripts after Mex3a deletion, but why is it that the reduction of Olfm4 does not equate to the robust reduction of Lgr5? Is it possible that Mex3a null intestines are not able to respond to Wnt signaling, leading to reduction of Lgr5 expression in ISCs, together with a direct impact on Paneth cells that respond to WNT. All of this could result in progressively less ISCs. 6. The Olfm4, Hopx and Lrig1 ISH needs quantification, since the current images do not properly show a convincing reduction of the transcripts. 7. I strongly suggest that the authors use a conditional knockout approach, which would allow them to definitively support their conclusions, as well as to explore ideas such as what is the difference, if any, in Mex3a requirement between the high and low Mex3a cells reported by Barriga et al. The authors state in lines 321-322, that: "Together, these results strongly suggest that MEX3A expression is required for maintenance of Lgr5+ stem cells in vivo." With the current genetic model, the authors cannot make this claim. A key experiment to conclude this would be to conditionally knockout Mex3a in Lgr5+ cells using an Lgr5CreER driver. 8. If Mex3a is required for Lgr5+ ISCs, why is it that in organoids Lgr5 expression levels are similar to wt organoids at day 4? 9. In Figure 7A , the author nicely show increased expression of PPARγ in the crypts of Mex3a-/mice. However, the authors state that in Mex3a-/-mice, PPARγ is expressed along the crypt-villus axis, and from their images, it actually seems that the villus expression is reduced in mutant mice. 10. One of main conclusions of the paper is that Lgr5+ ISCs are negatively impacted, in number and function, by the loss of Mex3a. To support this latter conclusion about function, the authors should carry out an Lgr5 lineage tracing experiment in vivo and in vitro. 11. The authors state in lines 591-593 that:"Furthermore, the results obtained with organoid culture indicate that the process is abnormal with delayed transition from spheroid to budding organoids." The delayed transition from spheroid to organoids is not shown. 12. The authors should measure Wnt/β-catenin target genes in vivo to assess the impact of MEX3A loss on ISCs and Paneth cells. 13 . A key point of the manuscript is that Lgr5+ ISCs are lost because of Mex3a genetic loss. However, with the current experiments the authors cannot conclude that, because the experiments presented here rely on a constitutive knockout genetic model. Mex3a genetic ablation should be done in specific cell populations, such as the Lgr5+ ISCs. Furthermore, as MEX3A is an RNA binding protein, it is hard to ignore its role in cells and tissues other than the intestine, which could be impacted by using a constitutive genetic model. Figure 5 panel A, diameter length is not a proper metric for organoid size and/or growth. 4. Figure 5 panel D, add label indicating the staining, which in this case is LYZ1. 5. Figure 5 panel G, immunofluorescent images are of low quality and the nuclei are not visible by their counterstain. Please improve these images. 6. Figure 7 panel A, add label indicating the staining, PPARγ in this case. 7. Figure 7 panel B, it is extremely difficult to conclude anything from these images, since the mRNA signal is extremely low. Please improve these images. 8. I recommend the authors use shorter incubation times for the RNAscope probes, which will decrease background.
How the small intestine develops postnatally in not well characterized, particularly during the transition period of weaning. Here, the authors show that Mex3a is required for proper intestinal development, particularly the transformation that occurs at the weaning stage. They proposed that Mex3a regulates Lgr5+ intestinal stem cells via suppression of PPARgamma. The study thoroughly characterizes the phenotype of Mex3a knockouts, but more data is required to convincingly support the link between the Mex3a knockout phenotype and Lgr5 ISC depletion to establish a functional relationship.
1. How do the authors reconcile the fact that SI development and lineage specification (except Paneth cells) are largely normal up until at least 2 weeks of postnatal life in the presence of nearcomplete loss of Lgr5+ ISCs as suggested by the in situ hybridization (ISH)? If there was a minimal number of functional Lgr5+ ISCs (and also other alternative stem cell pools as suggested by reduced Hopx and Lrig1 expression), wouldn't the authors expect a more drastic phenotype earlier? 2. To evaluate the presence of surviving Lgr5+ ISCs (perhaps due to some mosaicism from rescue from Mex3a paralogous members), can the authors use lineage tracing with Mex3aKO;Lgr5-EGFP-IRES-CreERT2;R26-conditional reporter (e.g. tdTomato) to show the turnover and what are the cell types that can be generated from the Mex3aKO ISCs? 3. Similar to point #1, with a marked reduction of Lgr5+ ISCs, how are the organoids sustainable? There is no mention of the longevity of the organoids derived from Mex3a knockout crypts in culture -Can they be propagated for as long as the WT crypts? Or can they only be propagated for a limited time? This reflects the functionality of Lgr5+ ISCs that remain in the organoids. 4. As the mouse model is a systemic constitutive knockout of Mex3a, can the authors perform transplantation of the organoids into a wildtype host to ascertain the ISC-specific phenotype? 5. It is difficult to reconcile the contrasting expression patterns of non-CBC-specific stem cell marks Hopx and Lrig1 in Mex3a knockout SI (in which they are downregulated) and organoids (in which they are upregulated). What do the authors make of these opposing observations? 6. RNASEQ and qPCR validation performed on only 2 mice per group -I disagree with what the authors said about the "high degree of similarity within genotypes" (line 411). Looking at the heatmap in Fig 6A , the 4 samples are visibly different from one another, and the two most similar samples are a Mex3a knockout and WT (two rightmost columns). Between the two Mex3a knockouts, the magnitudes of upregulation in the most highly upregulated genes are don't concur. Therefore, the authors should increase the sample size for the transcriptome profiling and qPCR validation as this has ramifications for the later PPARgamma story. 7. The authors need to show positive control PPIB for the ISH experiments to show that there is no global downregulation of all transcripts since Mex3a is an RNA binding protein. Relating to this point, the RNA in situ hybridization panels should be supported by qPCR data as well since qPCR allows for quantitative normalization of each tissue to a housekeeping gene and would address whether the lower expression of the stem cell markers are due to a global downregulation of gene expression (e.g. Figs 3, 4, 5F). 8. Can the authors perform the complementary experiment to Fig 7 and culture Mex3a knockout organoids in PPARgamma antagonist to see if it can partially rescue the morphological phenotype and increase Lgr5 expression?
The manuscript by Pereira and colleagues describes how Mex3a controls maintenance of Lgr5positive intestinal stem cells. The authors show that Mex3a is required for proliferation of ISCs as well as for differentiation of Paneth cells. They conclude that Mex3a negatively regulates PPARg protein levels in the crypt cells. They further demonstrate that PPARg signaling impairs growth of intestinal organoids. The manuscript is well written and of general interest. There is one point that need to be addressed to strengthen the conclusions the authors draw.
Major point:
Mex3a was ablated in both epithelium and mesenchyme. Therefore, it is possible that the absence of Wnt and other signals from the mesenchymal cells are responsible for the proliferation defects observed in the mutant mice. The expression of Wnts, BMP antagonists and EGF could be evaluated by qPCR analysis of the mesenchymal cells.
Minor point: Lane 466: The authors write: "MEX3A overexpression in Caco-2 cells led to a 70% decrease in PPARg protein levels ( Figure S6B )." However, based on their quantification, the protein levels are decreased to 70%. These is a 30% decrease only. Here, the authors should formulate the statement clearly.
1st Revision -authors' response 18 November 2019
EMBOR-2019-48938-T Referee comments:
Referee #1:
The authors of this interesting manuscript report a negative impact on Lgr5+ ISCs after constitutive Mex3a knockout. This study builds on a previous study by Barriga et al. 2017 by characterizing Mex3a expression in intestinal crypts and showing a role for Mex3a in intestinal epithelium maturation. In addition, they demonstrate that Mex3a null mice exhibit PPARγ activation in intestinal crypts in vivo, and that overactivation of the pathway in vitro results in impaired organoid
formation. The authors provide suggestive results linking MEX3A and PPAR signaling to ISCs postnatal maintenance. However, in order to support their conclusions and definitively show that there is a requirement for Mex3a for ISC development or maintenance, the authors should address the following comments.
Major comments:
1. Figure 1 should be moved to supplementary material or added as a panel to Figure 2 . The expression pattern of Mex3a has already been characterized by Barriga et al. Further, the colon panels do not add to the story, since the entire manuscript focuses on the small intestine. Finally, the authors should clarify the difference between Mex3a expression seen in the Barriga et al. paper, i.e. in +3-4 ISCs, and the expression they report here at the bottom of the crypts, which as they comment later in the manuscript might be due to the early postnatal stages they are using here. We appreciate that the Reviewer considers our study interesting. We agree with the Reviewer's suggestion and have now included the small intestine and colon panels in Fig EV1, which provides for the first time a comprehensive characterization of the Mex3a expression pattern in major organs of the mouse. Furthermore, we performed this analysis using the corresponding Mex3a KO tissues as the best possible control to confirm the specificity of the Mex3a mRNA in situ hybridization (ISH) probe. Thus, this characterization goes beyond the study by Barriga et al. 2017. Regarding the distinct Mex3a mRNA localization profile in the intestinal crypts between both studies, we hypothesize that it might be the result of the developmental time-point studied and made this point clearer in the Discussion section. In addition, distinct ISH probes were used to detect Mex3a (targeting the mRNA 3`UTR in Barriga et al. 2017 or the coding sequence in our study), which might lead to different outcomes as a result of RNA secondary structure or due to distinct occupancy profiles by trans-regulators (such as microRNAs or RNA-binding proteins). From a technical standpoint, this might affect the hybridization process, particularly in the case of the 3`UTR probe.
It will be informative to compare the villi length they measured in the already shorter ileum villi to the longer duodenum villi, as the mammalian gut shows an antero-posterior development axis.
The authors should also discuss the difference between the proximal and distal intestinal phenotype in Mex3a-/-mice. We thank the Reviewer for pointing this out. We also characterized the proximal small intestinal region of the Mex3a KO mice. The phenotype follows the same trend described for the distal part regarding histological alterations, but it is less pronounced. For instance, while a 22% decrease in crypt depth was observed in the proximal region of the Mex3a KO intestine, in the ileum we observed a 41% decrease, justifying our focused analysis in the most distal region. A possible explanation is that there are regional differences in the intestinal epithelial turnover dynamics. It is known that the ileum displays the fastest turnover rate in mice and rats (Leblond and Stevens, 1948; Darwich et al. 2014), making it more vulnerable to alterations in ISC numbers. Also, specific ISC markers like Bmi1 have an expression pattern apparently restricted to the proximal small intestine (Sangiorgi and Capecchi, 2008), providing an additional layer of plasticity that might offer some type of functional compensation in this region. The data on the proximal region is now included in Appendix Fig S2. 3. The authors need to do a more in depth characterization of the differentiated cell types, using specific cell markers for the different cell populations, for example: MUC2, CHGA, DLCK1, sucrase-isomaltase, ALDOB.
We partially disagree with the Reviewer on this point. We have provided a characterization of the main differentiated cell types in Fig EV2, where Sucrose-isomaltase staining (SIS) is already shown. We did not assess MUC2 expression but used alcian-blue periodic acid Schiff (AB-PAS) staining to label goblet cells. This histochemical technique labels mucins and in intestine the most abundant mucin is MUC2 that is produced by goblet cells, so the result is equivalent. Enteroendocrine cells were labelled with synaptophysin (SYP) and enterocytes were labeled with Villin (VIL1), SIS and CDX2. However, we had not assessed the tuft cell lineage using the DCLK1 marker and thank the Reviewer for pointing it out. We now provide this data in Fig 
Is not clear if the reduction in the number of proliferating cells reported here is due to a loss of these cells or because the crypts are smaller; it is possible that the proportion of proliferating cells are maintained. Proliferating cells should be quantify and corrected by crypt size or quantified using FACS.
We have now quantified the number of proliferating cells. The average number of KI67+ cells per crypt in Mex3a mutant mice is 6.56 ± 1.39 compared with 12.60 ± 1.07 in WT mice, a 48% difference. The significant lower number is a consequence of the loss of ISCs, as these are the ones that would originate the KI67+ TA population, as well as the Paneth and tuft cell lineages, which are almost absent. As requested, we normalized the number of KI67+ cells to crypt size. The proportion is not significantly different, although there is a tendency to be decreased in the Mex3a KO mice (0.35 ± 0.07 compared with 0.41 ± 0.01 in WT mice). This is not unexpected because crypt size, without a gain of any of the other populations, is in fact determined by the number of TA cells (the main cellular component of crypts). Due to loss of the Lgr5+ ISCs, there is no continuous replenishment of the TA cell population. Additionally, the remaining TA population will differentiate into other epithelial cell lineages (although slowly, as indicated by the BrdU incorporation assays), and so both events contribute to an overall reduction in the TA cell number and, consequently, smaller crypt size. This data is now included in Appendix Fig S3 . We agree this experiment would reinforce our data on the role of intestinal MEX3A expression in Lgr5+ cells. Unfortunately, we currently do not have such model and, as the Reviewer might recognize, we would not be able to establish it within a reasonable timeframe for this revision. Therefore, we must restrict our analysis to the genetic model at hand and consider its strengths while acknowledging its limitations. We want to emphasize that we are describing the first Mex3a deletion model, which is part of the MEX-3 family of RNA-binding proteins whose biological functions are not well known. The present study goes far beyond the two main existing publications studying MEX3A. One is our previous work, where we described an in vitro association between MEX3A, loss of differentiation and increased expression of ISC . This is an interesting observation and we will continue to pursue it, but a deeper understanding at this stage falls outside the scope of the current work, as it does not argue against the effect of Mex3a deletion in ISCs. Figure 7A , the author nicely show increased expression of PPARγ in the crypts of Mex3a-/mice. However, the authors state that in Mex3a-/-mice, PPARγ is expressed along the crypt-villus axis, and from their images, it actually seems that the villus expression is reduced in mutant mice. PPARγ expression is associated with intestinal differentiation, and its expression becomes compartmentalized as adult-type enterocytes migrate to occupy the entire villi (Chen et al., 2006). By looking carefully to Fig 5A, it is perceptible that suckling-type enterocytes at P16 (distinguishable due to the presence of large vacuoles) do not stain for PPARγ. Mex3a KO mice show an impaired epithelial turnover rate, and because of that this type of immature enterocytes is still present at P18 when they should already be replaced. This is the reason why the expression in the villi is not as strong as compared to WT controls. Most importantly, PPARγ is present in the Mex3a KO crypts. 11. The authors state in lines 591-593 that: "Furthermore, the results obtained with organoid culture indicate that the process is abnormal with delayed transition from spheroid to budding organoids." The delayed transition from spheroid to organoids is not shown.
In
We agree with the Reviewer that this transition was not illustrated. We have now included this data in Appendix Fig S4. 12 ISCs. Furthermore, as MEX3A is an RNA binding protein, it is hard to ignore its role in cells and tissues other than the intestine, which could be impacted by using a constitutive genetic model. We thank the Reviewer for this analysis. We are aware that we are only characterizing in depth the phenotype in the intestine and might be facing confounding effects due to alterations in other organs. However, the fact that the intestinal phenotype is the only striking alteration detected upon macroscopic observation and histological analysis of major organs, associated with a general failure of the animals to thrive within 3 weeks post-birth indicates that intestinal malfunction is a major cause of death. As stated in the response to point 7, we can make the claim that Mex3a genetic ablation leads to loss of Lgr5+ ISCs in the intestine because this is the observed outcome through different methodologies. What we cannot state is that this is the consequence of loss of Mex3a expression solely in the intestinal epithelial Lgr5+ cells. There might be a contribution of loss of expression from other cell types, particularly the mesenchyme, as the Reviewers point out. While we must consider this hypothesis due to the constitutive nature of our genetic model, we do find it very unlikely, based mainly on three evidences we provide: 1) the expression pattern of Mex3a, as it is much more expressed in the intestinal crypt than in any other compartment of the intestine; 2) when we combine loss of one Mex3a allele with loss of one Lgr5 allele we get the same phenotype observed with loss of the two Mex3a alleles, indicating a specific effect in the Lgr5+ cells; 3) we did not detect expression differences in genes coding for growth factors secreted by the Mex3a KO mesenchyme tissue in vivo nor an impact over stem cell self-renewal in the organoid culture system using KO mesenchymal-derived conditioned media. Still, in agreement with the Reviewers opinions, we have tried to clearly highlight the strengths and weaknesses of our genetic model in the Discussion section of the revised manuscript. We thank the Reviewer for pointing these out. The missing references were added to the revised manuscript.
Line 227 should read increased, instead of reduced?
We clarified this sentence.
Figure 5 panel A, diameter length is not a proper metric for organoid size and/or growth.
In this early stage (at day 2 after plating), freshly isolated crypts are essentially cystic/round structures. Hence, diameter length provides a good estimate of the size in this time-point.
Figure 5 panel D, add label indicating the staining, which in this case is LYZ1.
The label was added.
Figure 5 panel G, immunofluorescent images are of low quality and the nuclei are not visible by their counterstain. Please improve these images.
The resolution of the immunofluorescence images was improved.
6. Figure 7 panel A, add label indicating the staining, PPARγ in this case.
7. Figure 7 panel B , it is extremely difficult to conclude anything from these images, since the mRNA signal is extremely low. Please improve these images.
The resolution of the ISH images was improved.
I recommend the authors use shorter incubation times for the RNAscope probes, which will decrease background.
We thank the Reviewer for the suggestion.
Referee #2:
How do the authors reconcile the fact that SI development and lineage specification (except Paneth cells) are largely normal up until at least 2 weeks of postnatal life in the presence of nearcomplete loss of Lgr5+ ISCs as suggested by the in situ hybridization (ISH)? If there was a minimal number of functional Lgr5+ ISCs (and also other alternative stem cell pools as suggested by reduced Hopx and Lrig1 expression), wouldn't the authors expect a more drastic phenotype earlier?
We appreciate that the Reviewer recognizes the comprehensive nature of our report on the Mex3a Gradually during the second postnatal week, and sharply throughout the third postnatal week, crypt number increases through crypt fission, with a concomitant expansion of the number of ISCs and Paneth cells. Hence, for all the above mentioned reasons, abnormal ISC activity should be more noticeable at this period, when major structural and biochemical changes associated with weaning take place (for instance, mice start sampling solid food around P14), helping to explain why the onset of intestinal phenotype in the Mex3a KO mice primarily occurs during the P15-P21 time-window and not in earlier stages.
To evaluate the presence of surviving Lgr5+ ISCs (perhaps due to some mosaicism from rescue from Mex3a paralogous members), can the authors use lineage tracing with Mex3aKO;Lgr5-EGFP-IRES-CreERT2;R26-conditional reporter (e.g. tdTomato) to show the turnover and what are the cell types that can be generated from the Mex3aKO ISCs?
We agree that this experiment would allow us to follow the fate of the cell types generated from the Mex3a KO ISCs and turnover (please see also our response to Reviewer #1, point 10). Unfortunately, we do not have a Mex3a;Lgr5 lineage-tracing ready strain to conduct this experiment. Still, we believe the absence of Paneth and tuft cells, the BrdU pulse-chase experiments and the ultrastructural characterization of enterocytes, all demonstrate that there is a functional effect of Mex3a loss in Lgr5+ ISCs normal renewal.
Similar to point #1, with a marked reduction of Lgr5+ ISCs, how are the organoids sustainable?
There is no mention of the longevity of the organoids derived from Mex3a knockout crypts in culture -Can they be propagated for as long as the WT crypts? Or can they only be propagated for a limited time? This reflects the functionality of Lgr5+ ISCs that remain in the organoids. We described in the Results section that we did not detect differences in the longevity of organoids originating from Mex3a KO mice compared with the WT, at least for a period of 3 months of culture. What was strikingly different from the WT organoids was the growth dynamics within each passage. We hypothesize that Mex3a KO organoids are sustainable due to the combination of at least two factors: 1) there is essentially a Lgr5-cell population capable of initiating organoid growth from the KO crypts that gives rise to Lgr5+ cells in culture. This type of dynamic cellular transition has been observed in other models, including the Lgr5 DTR/+ mice in which Lgr5 KO crypts give rise to organoids with Lgr5+ cells in culture (Tian et al. 2011) . This is probably linked to the fact that routine organoid culture conditions stimulate conversion of different cells (possibly TA or already committed progenitors) to Lgr5+ cells due to the presence of Rspondin in the medium; 2) PPARγ baseline activity is not different between Mex3a KO and WT organoids, possibly due to modulation by components of the culture medium. This means that the Wnt pathway counteracting effect observed in vivo is possibly lost ex vivo. Moreover, culture conditions are enriched in Wnt pathway promoting signals and for that reason we can only see an impact of the PPARγ pathway when we use agonists. This feature of the PPARγ signalling pathway might decrease the relevance of Mex3a expression in the organoid system. Being an RBP, it actually makes sense because MEX3A is probably involved in rapid switches of target gene expression in response to external signals that are not faithfully recreated in culture (for example, no fluctuations in nutrient availability, no circadian rhythms, among others). These are hypothesis that we will explore in the future, but we believe fall outside the scope of the current work.
As the mouse model is a systemic constitutive knockout of Mex3a, can the authors perform transplantation of the organoids into a wildtype host to ascertain the ISC-specific phenotype?
We agree this would be an interesting experiment to better clarify the epithelial ISC-specific phenotype. However, to the best of our knowledge transplantation of organoids in a small intestinal context is not well established. Even transplantation into a colonic context is non-trivial and would require optimizing protocols of induced mucosal damage that would be overlong to establish within the timeframe of the revision. Alternatively, we have isolated mesenchymal cells from both WT and KO small intestinal tissue (after villi and crypt removal), established primary cultures, and produced conditioned media. We observed that it was possible to generate and passage both KO and WT organoids in the presence of either KO or WT mesenchymal cell-derived conditioned media. In addition, we also observed no significant differences in the KO mesenchymal tissue concerning the expression level of genes coding for specific growth factors (Egf, Nog, Rspo1, Wnt2b and Wnt3) suggesting that there is a minimal contribution of the mesenchyme for the observed phenotype.
It is difficult to reconcile the contrasting expression patterns of non-CBC-specific stem cell marks Hopx and Lrig1 in Mex3a knockout SI (in which they are downregulated) and organoids (in which they are upregulated). What do the authors make of these opposing observations?
The Reviewer raises a relevant point. In fact, by performing qPCR analysis, we could only confirm the decreased expression of Lrig1. This suggests that at least this reserve stem cell population is not able to functionally compensate for the loss of Lgr5+ ISCs in vivo. On the other hand, the expression of both markers is clearly detected in WT organoids (in the budding domains) and Mex3a KO spheroids (broadly present). In case of the latter, they might to some extent ensure organoid culture maintenance in early time-points when Lgr5 expression is decreased. This type of hierarchical plasticity is also observed in WT organoid cultures (Mustata et al. 2013; Smith et al. 2018 ). Fig 6A, the 4 samples are visibly different from one another, and the two most similar samples are a Mex3a knockout and WT (two rightmost columns). Between the two Mex3a knockouts, the magnitudes of upregulation in the most highly upregulated genes are don't concur. Therefore, the authors should increase the sample size for the transcriptome profiling and qPCR validation as this has ramifications for the later PPARgamma story. We agree with the Reviewer (and Reviewer #3, additional comments) and performed RNA-seq analysis in two additional pairs of Mex3a KO and WT mice at P16. In order to remove the confounding factor of age, we present the analysis of the three pairs of mice at P16 only (although when we add the P19 pair the results are quite similar). This data is now included in Fig 4. Due to the number of samples and higher degree of similarity, we were able to apply stringent statistical criteria (P value < 0.01 and -1.5 ≥ fold change ≥ 1.5) having obtained a list of 725 differentially expressed genes. Most of the individual genes, the biological processes involved, and most importantly the signalling pathways altered in the KO mice are the same when compared to our initial dataset, supporting the results obtained, particularly concerning PPARγ upregulation and significantly reinforcing Wnt signalling pathway downregulation.
RNASEQ and qPCR validation performed on only 2 mice per group -I disagree with what the authors said about the "high degree of similarity within genotypes" (line 411). Looking at the heatmap in
The authors need to show positive control PPIB for the ISH experiments to show that there is no global downregulation of all transcripts since Mex3a is an RNA binding protein. Relating to this point, the RNA in situ hybridization panels should be supported by qPCR data as well since qPCR allows for quantitative normalization of each tissue to a housekeeping gene and would address
whether the lower expression of the stem cell markers are due to a global downregulation of gene expression (e.g. Figs 3, 4, 5F) . We performed ISH for Ppib (positive control) and DapB (negative control) in Mex3a KO and WT mice intestinal tissues by routine practice to confirm optimal fixation conditions for the RNAscope ISH staining. We did not observe differences between both mice concerning Ppib levels (please see Reviewer Figure 2 below). Global downregulation of all transcripts would not be expected as MEX3A is not a "housekeeping" RBP. Additionally, taking into account our previous work and what is described for C. elegans, MEX3A might act at the level of translation, thus differences in mRNA expression levels of direct targets might not be detected. We have performed qPCR for the stem cell markers in isolated crypt fractions and the analysis is now included in Fig 2L. Reviewer Figure 2 . ISH for Ppib mRNA, a housekeeping gene, in WT and Mex3a KO mice.
Can the authors perform the complementary experiment to Fig 7 and culture Mex3a knockout organoids in PPARgamma antagonist to see if it can partially rescue the morphological phenotype and increase Lgr5 expression?
Treatment of organoids with the specific PPARγ antagonist SR2595 did not alter organoid growth or self-renewal ability nor Lgr5 expression, reinforcing that the WT and KO organoids have an equally low level of PPARγ pathway baseline activity.
Referee #3:
The manuscript by Pereira and colleagues describes how Mex3a controls maintenance of Lgr5positive intestinal stem cells. The authors show that Mex3a is required for proliferation of ISCs as well as for differentiation of Paneth cells. They conclude that Mex3a negatively regulates PPARg protein levels in the crypt cells. They further demonstrate that PPARg signaling impairs growth of intestinal organoids. The manuscript is well written and of general interest.
There is one point that need to be addressed to strengthen the conclusions the authors draw.
Major point:
Mex3a was ablated in both epithelium and mesenchyme. Therefore, it is possible that the absence of Wnt and other signals from the mesenchymal cells are responsible for the proliferation defects observed in the mutant mice. The expression of Wnts, BMP antagonists and EGF could be evaluated by qPCR analysis of the mesenchymal cells. We appreciate that the Reviewer considers our manuscript well written and of general interest. We agree with this point. No significant differences were detected in the KO mesenchymal tissue concerning the expression level of genes coding for specific growth factors (Egf, Nog, Rspo1, Wnt2b and Wnt3), indicating that Mex3a ablation does not alter the expression profile of mesenchymal genes relevant for ISCs maintenance.
Minor point:
Lane 466: The authors write: "MEX3A overexpression in Caco-2 cells led to a 70% decrease in PPARγ protein levels ( Figure S6B) ." However, based on their quantification, the protein levels are decreased to 70%. These is a 30% decrease only. Here, the authors should formulate the statement clearly. We respectfully disagree with the Reviewer, as the statement is correct. Quantification of PPARγ protein levels upon MEX3A overexpression (PPARγ bar, middle panel) indeed reveals around 70% decrease in protein expression relative to the Caco-2 mock cell line. ****
Additional comments Referee #3:
I agree that the study has several weak points to fully support the conclusions of the authors. It has also a technical weakness in RNA-seq analysis.
1. All referees requested either cell type specific Mex3a knock-out or evidences that mesenchymal cells express the signals required for ISC maintenance/ Paneth cell differentiation. The authors propose that Mex3a functions in the intestinal epithelium for the maintenance of ISCs. To provide evidences for the epithelium specific functions of Mex3a they used ex vivo organoid assays and measured cell growth and the expression of marker genes. Figures 5A and 5C show that organoids grow slower, and the expression of Axin2, Lgr5, Lyz1 markers is 2 times lower in the KO versus wt organoids at day 2. However, at day 4 both KO and wt organoids express Axin2 (TA cell marker) and Lgr5 (stem cell marker) at the same level ( Figure 5E ) and organoids are of a similar size as wt ( Figure 5B and 5D) . Moreover, the expression of TA cell markers Hopx and Lrig1 are strongly induced in KO organoids exposed to the external growth factors. The organoids could be maintained for months in culture. Therefore, proliferation and ISC/ TA marker expression defects in Mex3a KO mice could be rescued by culturing the epithelial cells with appropriate external growth factors. This indicates that either Mex3a is required in the mesenchymal cells of the gut or it is required for differentiation/ maturation of Paneth cells. Based on the data provided in the current manuscript it is not possible to conclude. Based on the loss of Lgr5+ ISCs in the Mex3a KO and the link with PPARγ signalling, our hypothesis is that MEX3A is involved in the regulation of ISCs response to external signals. These signals might operate differently in the organoid culture system or might be entirely lost due to the static properties of the culture. Hence, Mex3a does not seem required to ensure organoid maintenance (please see our answer to Reviewer #1, point 8). Although we cannot formally exclude that Mex3a is required in the mesenchymal compartment due to the constitutive nature of our model, it seems more plausible, also based on the PPARγ results, that the role of MEX3A is centred on epithelial ISCs (please see our answer to Reviewer #1, point 7). Concerning the second point, the lack of Paneth cells in vivo could be due either to an impairment of ISC differentiation into this lineage or to a drastic reduction in the number of ISCs that originate them. We do not see a blockade in Paneth cell differentiation, as we are still able to detect them in vivo although at very low numbers, and in the Mex3a KO organoid cultures, although with a delayed appearance. Hence, we favour the second hypothesis, as there is a strong reduction in the number of Lgr5+ ISCs in vivo an in vitro (in initial days of culture).
2. Referee 2 (point 8) has proposed a very good functional assay, however, it cannot be performed for the following reason. Ex vivo, neither pparg nor its target genes are significantly upregulated in Mex3a KO compared to wt organoids. PPARg is not expressed in the crypt compartment in WT conditions. Since KO cells also do not express it in culture this indicates that the external growth factors influence the expression of PPARg targets in the epithelial cells. We appreciate the Reviewer detailed analysis and fully agree with it. Still, we performed this experiment and as expected observed no changes in organoid growth or self-renewal ability nor Lgr5 expression upon treatment with a specific PPARγ antagonist.
3. Referee 2 (point 6) finds that mex3a KO is closer to wt in one replicate. This is absolutely right. I have not seen whether the authors indicated that RNA-seq was performed using animals of different age. One pair was at P16 and the other at P19. This is the period when the gut is changing so much. It is why, the samples are separated by age and not by genotype. To be precise, the RNA-seq is done on 1 replicate at different time points. They should provide more replicates at least for one stage. We agree with the Reviewer analysis (please see also our response to Reviewer #2, point 6) and performed RNA-seq analysis in two additional pairs of Mex3a KO and WT mice at P16. This data is now included in Fig 4. Most of the individual genes, the biological processes involved, and most importantly the signalling pathways altered in the KO mice are the same when compared to our initial dataset, supporting the results obtained, particularly concerning PPARγ.
2nd Editorial Decision 13 January 2020
Thank you for the submission of your revised manuscript to our editorial offices. We have now received the reports from the three referees that were asked to re-evaluate your study, you will find below. As you will see, referees #1 and #3 now support the publication of your study in EMBO reports. Referee #2 remains critical, insisting on a conditional KO approach we have agreed as out of scope of the current study. We thus do not require a conditional mouse model. Nevertheless, please address this referees concerns regarding the quality of the panels (the referee indicates are poorly fixed). Moreover, referee #3 has a final point regarding the correlation between BMI1 as a supposedly proximal stem cell marker and region-specific KO phenotypes. Since Bmi1 has conclusively been shown to be widely expressed throughout all regions of the intestine, this correlation is not valid and needs to be revised accordingly. Please do that. Please also provide a point-by-point-response to these remaining concerns case.
Further, I have these editorial requests:
-Please provide the abstract written throughout in present tense.
-Please move all material and methods information from the Appendix to the main manuscript, and delete these in the Appendix.
-In the author contributions Valdemar Maximo is missing. Please check and provide his contribution.
-Please go again through all the figure legends, INCLUDING those of the Appendix, and make sure that, where applicable, the number "n" for how many independent experiments (biological replicates) were performed is indicated, the bars and error bars (e.g. SEM, SD) are defined, and the test used to calculate p-values is indicated.
-Please go through all the figure legends, INCLUDING those of the Appendix, and assure that all the scale bars are defined in the legend. It seems at least in the Appendix this is not always the case.
-There seems to be no call-out for Figure 4D in the manuscript text. Please check.
-In the diagrams of Figs. 4H and EV4 you show error bars and/or statistical testing (for 4H), although you indicate in the legend that only two replicates are shown. Thus, statistical testing does not make much sense here (with two replicates). Please show these data without statistics and error bars, by showing the two dataset separated (e.g. one bar for each replicate).
- Table 1 is too long to be shown online in the manuscript. This needs to be a dataset (data files that will be linked to the article). Please upload this file as Dataset file, named Dataset EV1. Please add the legends for this datasets as a new TAB to the respective excel file (as first TAB). Please also update the callouts for this file in the manuscript text. Finally, please remove the legend for this table from the manuscript text.
-As it does not contain main data, I suggest to move -Please remove the reviewer access information from the data availability section and make sure that the data gets public upon publication of the study.
-Finally, please find attached a word file of the manuscript text (provided by our publisher) with changes we ask you to include in your final manuscript text, and some queries, we ask you to address. I think you have already addressed these. But please re-check and provide your final manuscript file with track changes, in order that we can see the modifications done.
In addition I would need from you: -a short, two-sentence summary of the manuscript -two to three bullet points highlighting the key findings of your study -a schematic summary figure (in jpeg or tiff format with the exact width of 550 pixels and a height of not more than 400 pixels) that can be used as a visual synopsis on our website.
I look forward to seeing the final revised version of your manuscript when it is ready. Please let me know if you have questions regarding the revision.
REFEREE REPORTS
Referee #1 (referee #3 from TEJ submission):
I have read both the revised manuscript and the comments of the authors. I think they have addressed everything satisfactory. I recommend publication of this work.
---------------Referee #2 (referee #1 from TEJ submission):
This paper provides an initial characterization of the Mex3a KO in the gut. The authors are to be commended for their thoughtful responses to the reviews, but the initial critiques by me and others still hold, specifically, that a conditional KO approach is essential in order to make claims about the role of Mex3a in ISCs. Additionally, the quality of the data could be improved, with the tissue being poorly fixed in most of the panels. I do think that the paper would be a contribution to the literature, but it might be more appropriate in a more specialized journal.
---------------Referee #3 (referee #2 from TEJ submission):
Although the lack of a conditional model and/or transplant experiments somewhat dilutes their major conclusions, the authors have done a good job of addressing the major technical concerns -in particular increasing the biological replicates.
I would hope that such an experienced intestinal biology group would not continue to propagate the myth that Bmi1 is selectively marking proximal stem cells simply to justify their observed regional differences in the KO phenotype. Multiple studies have conclusively shown that Bmi1 is broadly expressed in crypts from all regions of the intestine, highlighting the poor fidelity of the reporter models being used by Capecchi's group.
2nd Revision -authors' response 15 January 2020
EMBOR-2019-48938V2 Referee comments:
Referee #1 (referee #3 from TEJ submission)
I have read both the revised manuscript and the comments of the authors. I think they have addressed everything satisfactory. I recommend publication of this work. We thank the Reviewer for the help improving the manuscript.
Referee #2 (referee #1 from TEJ submission)
This paper provides an initial characterization of the Mex3a KO in the gut. The authors are to be commended for their thoughtful responses to the reviews, but the initial critiques by me and others still hold, specifically, that a conditional KO approach is essential in order to make claims about the role of Mex3a in ISCs. Additionally, the quality of the data could be improved, with the tissue being poorly fixed in most of the panels. I do think that the paper would be a contribution to the literature, but it might be more appropriate in a more specialized journal. We thank the Reviewer for the comments and the help improving the manuscript. Regarding the comment on the quality of the data, in accordance with the best histopathological practices, whole intestinal tracts were removed immediately after mice euthanasia and placed in 10% neutral buffered formalin fixative for a period of at least 72h to allow optimal tissue penetration. Our processed and stained tissue slides were examined by a pathologist (co-author Leonor David). We do not detect in the reported panels any signs of poor fixation, such as tissue autolysis, heterogeneous staining of cells within the same region or indistinct subcellular structures. On the contrary, and as an example, we can clearly observe nucleoli within nuclei in H&E staining, an indication of good fixation conditions. We believe the Reviewer might be misled by the ISH panels where a green solution was used as counterstain for the red chromogen. Since this is a cytoplasmatic counterstain, the nuclei are not stained, and tissue morphology is not so defined in appearance. On the other hand, this counterstain offers good contrast to the ISH signals, better highlighting them (particularly when they are weaker), which was why we used it.
Referee #3 (referee #2 from TEJ submission)
Although the lack of a conditional model and/or transplant experiments somewhat dilutes their major conclusions, the authors have done a good job of addressing the major technical concernsin particular increasing the biological replicates.
I would hope that such an experienced intestinal biology group would not continue to propagate the myth that Bmi1 is selectively marking proximal stem cells simply to justify their observed regional differences in the KO phenotype. Multiple studies have conclusively shown that Bmi1 is broadly expressed in crypts from all regions of the intestine, highlighting the poor fidelity of the reporter models being used by Capecchi's group. We thank the Reviewer for the comments and the help improving the manuscript. We agree with the Reviewer`s view on Do the data meet the assumptions of the tests (e.g., normal distribution)? Describe any methods used to assess it.
Is there an estimate of variation within each group of data?
Is the variance similar between the groups that are being statistically compared?
Given this was the first Mex3a KO mouse established, we did not know a priori the phenotypic manifestations of the strain. We defined for most of the experimental work that a minimum of n = 3 mice for each genotype and in at least three different postnatal developmental time-points would be required to recognize biologically meaningful differences between genotypes.
Criteria to include a Mex3a KO animal in the cohort of analysed animals were pre-established and based on humane endpoints for euthanasia. Specifically, weights were monitored 3 times a week and the presentation of the following clinical signs were used to euthanize animals: gradual weight loss during 3 consecutive weigh-ins, dehydration, lethargy, and reluctance to move when stimulated. Age-matched or littermate WT controls of the same gender were used for comparative studies. Genotype of the animals was always confirmed using specific primer pairs (Table 2) by collecting a minimal portion of tail between P1-P3. NA
Manuscript Number: EMBOR-2019-48938V2
Statistical tests were chosen accordingly.
Yes. When applicable, we analyzed if our data followed a normal distribution using the D'Agostino-Pearson normality test.
When applicable, we estimated variation using an F-test of equality of variances.
Yes.
To minimize the effects of subjective bias (variation in litter size, maternal behaviour, variation in animal house environmental conditions), we analysed pups from different litters (each litter was defined as the experimental unit) for the different experiments.
Yes, there was blinding of researchers assessing phenotypic outcomes. Tissue samples were identified by animal number and assessment (or quantifications) of phenotypes were performed blind to the animal genotype.
Data
the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner. figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified the exact sample size (n) for each experimental group/condition, given as a number, not a range;
Each figure caption should contain the following information, for each panel where they are relevant:
Captions
The data shown in figures should satisfy the following conditions:
Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation.
Please fill out these boxes ê (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name).
NA
B-Statistics and general methods
the assay(s) and method(s) used to carry out the reported observations and measurements an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner. a statement of how many times the experiment shown was independently replicated in the laboratory.
Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
In the pink boxes below, please ensure that the answers to the following questions are reported in the manuscript itself. Every question should be answered. If the question is not relevant to your research, please write NA (non applicable). We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects.
definitions of statistical methods and measures:
a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
EMBO PRESS
A-Figures
Reporting Checklist For Life Sciences Articles (Rev. June 2017)
This checklist is used to ensure good reporting standards and to improve the reproducibility of published results. These guidelines are consistent with the Principles and Guidelines for Reporting Preclinical Research issued by the NIH in 2014. Please follow the journal's authorship guidelines in preparing your manuscript.
PLEASE NOTE THAT THIS CHECKLIST WILL BE PUBLISHED ALONGSIDE YOUR PAPER Journal Submitted to: EMBO Reports
Corresponding Author Name: Bruno Pereira YOU MUST COMPLETE ALL CELLS WITH A PINK BACKGROUND ê
